Voyager Therapeutics Revenue, Profits - VYGR Annual Income Statement

Add to My Stocks
$22.5 $1.33 (6.28%) VYGR stock closing price Jun 21, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the Voyager Therapeutics stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from 14.22M to 10.13M and how operating and non operating activities have impacted the VYGR stock. The Voyager Therapeutics profit and loss statement for 2017 shows a net profit of $-70.69M. Profits for last year was $-40.19M. Apart from this an investor should also check Voyager Therapeutics assets and Voyager Therapeutics free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Fiscal year is Jan - Dec20172016201520142013
Voyager Therapeutics Revenues or Net Sales
10.13M14.22M17.33M--
Cost Of Goods Sold (COGS)-----
Voyager Therapeutics Gross Profit
10.13M14.22M17.33M--
Research & Development Expense62.26M42.24M27.67M8.89M2.31M
Selling General & Admin Expense19.73M13.27M9.9M5.46M1.45M
Income Before Depreciation Depletion Amortization-71.86M-41.29M-20.25M-14.36M-3.76M
Depreciation Depletion Amortization-----
Non Operating Income1.16M1.15M-9.41M-1.95M-0.06M
Interest Expense-----
Voyager Therapeutics Pretax Income
-70.69M-40.14M-29.67M-16.31M-3.83M
Provision for Income Taxes-----
MinorityInterest-----
Investment Gains Losses-----
Other Income-----
Income Before Extraordinaries & Disc Operations-70.69M-40.19M-29.67M-16.31M-3.83M
Extraordinary Items & Discontinued Operations-----
Voyager Therapeutics Profit/ Loss (Net Income)
-70.69M-40.19M-29.67M-16.31M-3.83M
Average Shares used to compute Diluted EPS26.8M25.3M4.19M--
Average Shares used to compute Basic EPS26.8M25.3M4.19M--
Income Before Nonrecurring Items-70.7M-40.19M-29.67M-16.32M-
Income from Nonrecurring Items-----
Voyager Therapeutics Earnings Per Share Basic Net
-2.64-1.59-9.14-27.83-
Voyager Therapeutics Earnings Per Share Diluted Net
-2.64-1.59-9.14-27.83-
EPS Diluted Before Nonrecurring Items-2.64-1.59-9.14-27.83-
Preferred Dividends Acc Pd-----
Dividends Common-----
Dividend Per Share Common0.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.

Before investing one should read a report on Voyager Therapeutics stock analysis. It helps to look at the following income statement items:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that VYGR stock has a topline or revenue of $10.13M for 2017 as per this Voyager Therapeutics revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-70.69M for Voyager Therapeutics for 2017. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called statement of revenue and expense. The VYGR financials along with Voyager Therapeutics historical stock prices provide a lot of details about the firm.

Voyager Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
69.89
Dividend Yield
0%